Sangamo, Pfizer Unite to Develop SB-525 Hemophilia A Gene Therapy – Hemophilia News Today
|
Sangamo, Pfizer Unite to Develop SB-525 Hemophilia A Gene Therapy
Hemophilia News Today “We believe Pfizer's end-to-end gene therapy capabilities will enable comprehensive development and commercialization of SB-525, which could potentially benefit hemophilia A patients around the world,” added Sandy Macrae, PhD, Sangamo's president … |
